121 results about "Ocular surface" patented technology

The invention relates to the technical field of medical medicines, and discloses a composition for relieving eye strong light burn and a preparation method thereof. The composition is prepared from the following components in percentage by weight: 0.5 to 3 percent of sodium aliphatate, 30 to 50 percent of corn starch, 25 to 45 percent of talcum powder, 1 to 4 percent of cresol, 5 to 15 percent of flos chrysanthemi indici, 0.05 to 0.5 percent of radix scutellariae, 0.01 to 0.1 percent of flos carthami, 0.1 to 1 percent of aqueous solvent and the balance of water. The preparation method comprises the following steps: crushing medicinal materials; preparing a water-phase matrix containing a water-based solvent and sodium aliphatate; performing dry mixing on corn starch, talcum powder and the medicinal material fine powder; and mixing the water phase and the solid phase, adding cresol, homogenizing, adjusting the pH value, and sterilizing to obtain a paste or pasty composition. The composition can effectively relieve ocular surface pain, lacrimation and foreign body sensation caused by strong light burn through cooperation of multiple ways of physical protection, anti-inflammatory repair and oxidation resistance.

The invention provides a nanoparticle penetrating cornea as well as a preparation method and application thereof. The nanoparticle comprises a cationic liposome G2-C14, an inner core formed by aliphatic polyester and an amphiphilic polymer, and a shell modified by polysaccharide, the hydrophobic drug and the siRNA are loaded in the inner core. According to the nano-particles provided by the invention, through polysaccharide surface modification, ocular surface adhesion and trans-epithelium transport capability are enhanced, multi-barrier penetration of the eye is realized, the nano-particles are effectively delivered to a focus area of posterior segment of the eye, the delivered siRNA targets to silence the expression of age-related macular degeneration pathogenic genes, and the hydrophobic drug removes active oxygen and inhibits release of inflammatory factors, so that the anti-aging effect of the nano-particles is improved. The focus thickness is synergistically reduced.

The present invention provides formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I) and methods for treating ocular surface pain by administering such formulations. The present invention also provides methods for treating dry eye disease and ocular hyperemia by administering formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4 H-quinazolin-3-yl)-benzonitrile.

An amniotic membrane insert configured for self-retaining, sutureless, clear-cornea application to an ocular surface. The insert has an outer edge and an inner edge inside the outer edge. The inner edge defines an opening sized to extend around a circumference of a cornea. The outer edge of the insert has a shape that is non-circular in which a height of the insert is greater than a width of the insert. Related devices, systems, and methods are provided.

The application provides an eye Tibetan medicine composition, a preparation and a preparation method and application thereof, and relates to the technical field of dry eye. The eye Tibetan medicine composition contains 80-120 parts by weight of berberis bark extract and 80-120 parts by weight of Qinghai dracocephalum extract. The eye preparation is prepared by mixing the eye Tibetan medicine composition and a solvent. The eye preparation can repair ocular surface tissue damage caused by dry eye and restore the normal secretion function of lacrimal glands.

The invention relates to the technical field of medical preparations, in particular to moisturizing and repairing type artificial tear as well as a preparation method and application thereof. Comprising the following steps: preparing effective components including high-molecular-weight polydeoxyribonucleotide and hyaluronic acid or a salt thereof into a homogeneous-phase stable composite solution, sterilizing, filtering, and aseptically packaging, the artificial tear formed by selecting high-molecular-weight polydeoxyribonucleotide and high-molecular-weight sodium hyaluronate as effective components has a relatively good repairing effect on tissues, can form long-term moisturizing and lubrication on ocular surfaces, is suitable for treating xerophthalmia, repairing cornea, relieving inflammatory response and the like, and has a good application prospect. Important market values and clinical application prospects are realized.

This invention involves co-transfecting cells with an AAV vector plasmid carrying the target gene, a packaging plasmid providing Rep / Cap proteins, and a helper plasmid providing adenovirus assistance. The transfected cells are cultured under suitable conditions to produce viral particles containing recombinant AAV. Cells and culture supernatant are collected, cells are lysed to release the virus, and the viral particles are purified by centrifugation. A membrane-penetrating peptides or their derivatives are then modified onto the AAV capsid protein. Results show that the gene editing system combined with membrane-penetrating peptides or their derivatives enhances editing efficiency, effectively penetrates ocular surface tissues, and inhibits ocular neovascularization.

Disclosed are methods, systems, media, apparatus, devices, and other implementations, including a method that includes determining blood flow characteristics at an ocular surface of an eye of a patient, determining characteristics of blood vessels at the ocular surface of the eye based on the determined blood flow characteristics, and deriving one or more ocular redness grading scales indicative of inflammation levels of the eye of the patient based on the determined characteristics of the blood vessels at the ocular surface of the eye.

A method for continual monitoring of a tear film integrity of a user's eye. Method includes determining a blink pattern of user's eye, using a means for detecting blinks of user's eye; measuring a temperature of an ocular surface of user's eye, at a set of at least two time instants within an inter-blink time interval of user's eye, using at least one temperature sensor; determining a rate of change in measured temperature for set of at least two time instants, based on a time interval between set of at least two time instants; comparing rate of change in measured temperature with a first threshold value; and when rate of change in measured temperature is greater than first threshold value: deeming tear film integrity of user's eye as broken.

This invention discloses a blueberry anthocyanin nutritional solid composition for relieving eye discomfort. The composition comprises blueberry anthocyanin solid powder, algal oil powder, zinc gluconate, and selenium-enriched yeast, and may optionally contain lipid nutrients containing gamma-linolenic acid, as well as food additives and excipients. Oral administration of this composition provides the body with various nutritional supports related to ocular surface function and ocular moisture, helping to maintain tear secretion levels, improve tear film stability, and support the normal physiological state of the corneal epithelium, thereby relieving eye dryness and discomfort caused by environmental stimuli or increased eye strain. Animal experiments showed that after 14 days of continuous administration of the composition, experimental mice exhibited a significantly increased tear secretion volume compared to the control group without the composition, with an increase of approximately 165%. Corneal fluorescein staining scores were also significantly reduced, indicating improved ocular surface condition and significantly enhanced eye comfort.

Disclosed herein are methods for treating an ocular surface disorder by administering a therapeutically effective amount of at least one lysophosphatidic acid receptor (LPAR) modulator to a subject.

The invention relates to the technical field of medical instruments, in particular to a frameless amniotic membrane mirror device, a manufacturing method and a using method, and the frameless amniotic membrane mirror device comprises an amniotic membrane tissue layer and a biocompatible thin film layer formed by spraying a mixed solution of polymethyl acrylate and polyvinyl alcohol; the overall diameter of the device is 14 mm, the rise of the device is 6.2 + / -0.1 mm, and the device can be directly implanted into the ocular surface to cover the cornea without a frame support. The manufacturing method comprises the steps of amniotic membrane treatment, model eye forming, mixed solution preparation, membrane spraying and forming, trimming and sterilization. The application method relates to implantation after surface anesthesia, fitting observation and subsequent taking-out. Through the frameless conformal fitting design, the problems that an existing framed amniotic membrane mirror is displaced and cannot be worn by a patient with strong foreign body sensation and shallow conjunctival sac are solved, and meanwhile secondary trauma of a suture operation is avoided. And the residual film after the amniotic membrane is dissolved can continuously provide protection, and the amniotic membrane has the advantages of good fitness, high patient comfort, simplicity and convenience in operation and good safety.

The utility model relates to the field of medical instruments, and discloses an auxiliary wearing device for a corneal bandage mirror, which comprises a mirror bracket, the mirror bracket comprises two mirror frames, each mirror frame is fixedly connected with a mirror leg, and a through space is arranged in each mirror frame; the number of the separating mechanisms is four, each glasses frame is connected with two separating mechanisms, the two separating mechanisms on the same glasses frame are used for separating the upper eyelids from the lower eyelids and opening the eyelids, and each separating mechanism comprises a rotating arm rotationally installed on the corresponding glasses frame and a patch rotationally installed on the rotating arm and used for being attached to the eyelids; the manual mechanism is manually operated and is used for applying a rotating acting force to the rotating arm; the distribution direction of the two glasses frames is the X direction, the wearing direction of the glasses frame is the Y direction, the distribution direction of the two groups of separating mechanisms on the same glasses frame is the Z direction, and the X direction, the Y direction and the Z direction are perpendicular to each other, so that hands are prevented from being in direct contact with eyelids, the occurrence probability of ocular surface inflammation is reduced, and the glasses are safer and more sanitary.

1. Name of the product in this design: Eye Surface Sample Sampling Bottle. 2. Purpose of this design: A tool for detecting pathogenic microorganisms in conjunctivitis secretions. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key points: 3D view 1. 5. Part A is marked as being made of transparent material.

A system for tracking delivery of a medication to a user’s eye and a method of use. The system comprises at least one camera for capturing one or more images of an eye surface of the user’s eye before, during, and after a time when the medication is applied to the user’s eye. The images captured are visual or thermal images, and for example, a temperature of the eye, eyelid, and periocular surfaces may be captured as well as visualization of the location of the eyelid or iris. If a second camera is used, it may be the same or different type of camera as the first camera and may capture one or more second images of the user’s eye before, during, and after the time when the droplets of the medication are applied to the user’s eye. A processor is provided for comparing the first images captures and / or comparing the first images to the second images, in order to determine when to deploy the droplets and / or if the droplets of the medication were successfully applied to the user’s eye.

The invention belongs to the technical field of medicines, and particularly relates to an active ingredient composition for treating xerophthalmia and muscae volitantes as well as a preparation method and application of the active ingredient composition. The composition is prepared from lycium barbarum polysaccharide, zeaxanthine, apigenin, luteolin, zinc gluconate, ophiopogon japonicus polysaccharide, ophiopogonin B, paeoniflorin and gallic acid according to a specific weight part ratio, all the active ingredients have a synergistic effect, the ocular surface microenvironment is improved, the vitreous opacity progress is inhibited, eye tissue damage is repaired, and the eye quality is improved. The synergistic treatment effect on the xerophthalmia and the muscae volitantes is achieved, and the symptoms such as eye dryness, eye acerbity, lacrimal secretion insufficiency, black shadow fluttering and blurred vision can be effectively relieved.

Disclosed herein are cold slurry formulations, devices, and methods for alleviating symptoms of ocular surface discomfort. Cold slurry formulations comprising ice, a freezing temperature depressant, and, optionally, a lipid are disclosed. Devices and methods for protecting a target ocular surface from contacting a cold slurry formulation that is used to maintain the target ocular surface at a temperature desired for alleviating symptoms of ocular surface discomfort are disclosed. Self-contained devices configured to receive a cold slurry formulation for maintaining the target ocular surface at a temperature desired for alleviating symptoms of ocular surface discomfort are disclosed. Devices and methods are disclosed for protecting a cornea and / or eyelid of a subject from the freezing cold slurry formulation that is directly or indirectly applied or injected into the target ocular surface. Kits comprising multiple syringes for administering multiple doses of the cold slurry to the target ocular surface, are disclosed.

An ocular surface image optimization method and apparatus, a portable ocular surface imager, and an electronic device, relating to the technical field of multispectral imaging. The method comprises: acquiring a target number of real-time frames, and performing grid division on the real-time frames to obtain target grids on the real-time frames; calculating a preset modulation transfer function in the target grids to obtain sharpness values, and mapping the sharpness values of the target grids corresponding to a single real-time frame to form an image-quality spatial map of a target size; and using a differential fitting algorithm to synthesize the image-quality spatial maps corresponding to the real-time frames into one target image-quality spatial map, generating an optimized image on the basis of the target image-quality spatial map, and sending the optimized image to a portable ocular surface imager for output. By dividing the real-time frames into different grids and calculating the modulation transfer function on a per-grid basis, the calculation speed is increased, and the problem that optimized images cannot be calculated in real time on the basis of multiple frames of images is solved.

The application provides a traditional Chinese medicine preparation for treating dry eye, and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicine preparations. The traditional Chinese medicine preparation comprises the following components in parts by weight: 8-12 parts of chrysanthemum, 8-12 parts of cassia seed, and 8-12 parts of Coptis chinensis / Scutellaria baicalensis. The compatibility and synergistic effect of chrysanthemum, cassia seed and Coptis chinensis / Scutellaria baicalensis in the traditional Chinese medicine preparation, and the drug administration mode of atomization fumigation can make the drug directly act on the ocular surface, improve the local drug concentration, compared with the existing method of simply using sodium hyaluronate eye drops, the preparation can effectively improve the ocular surface inflammation, improve the tear film stability, and fundamentally relieve the core symptoms such as dryness and fatigue of dry eye.

The present disclosure is directed to an ex vivo eye model system for screening ocular products with programmable blinking and tear flow control. In one example implementation, the ex vivo eye model system includes an eyeball core, an upper and lower eyelid frame, a servo, and a tear fluid delivery system. The eyeball core may be configured to hold a biological eye. The upper eyelid frame and the lower eyelid frame may be configured to replicate natural blinking actions and interact with the biological eye. The servo may be operatively connected to the upper eyelid frame and the lower eyelid frame. The servo may be configured to simulate controlled blinking actions by actuating the upper eyelid frame and the lower eyelid frame to move corresponding eyelid membranes of the biological eye. The tear fluid delivery system configured to deliver a fluid to an ocular surface of the biological eye.

The invention relates to a drug sustained release system, in particular to lipid liquid crystal precursor eye drops as well as a preparation method and application thereof. The lipid liquid crystal precursor eye drops comprise a matrix material, a cosolvent and a raw material medicine, wherein the matrix material is an amphiphilic substance and an oil phase; the lipid liquid crystal precursor eye drops are prepared from the following components in percentage by weight: 0 to 35 percent of amphiphilic substance, 40 to 80 percent of oil phase, 15 to 20 percent of cosolvent and 0.001 to 5 percent of raw material medicine. According to the constructed drug-loaded lipid liquid crystal precursor eye drops, when the drug-loaded lipid liquid crystal precursor makes contact with water in tears, the drug-loaded lipid liquid crystal precursor can instantly become drug-loaded lipid liquid crystal gel, compared with common eye drops, the retention time of the drug-loaded lipid liquid crystal gel on the ocular surface is longer, the lipid liquid crystal has a phospholipid bilayer structure, and the drug-loaded lipid liquid crystal gel can be used for preparing the drug-loaded lipid liquid crystal precursor eye drops. Insoluble raw material medicines can be distributed in the lipid layer, so that the solubility of the raw material medicines is greatly improved, the raw material medicines can be slowly released by gelatinizing after meeting water, the administration frequency is reduced, the bioavailability and patient compliance are greatly improved, and the defects of the eye drops in treatment of glaucoma are overcome.

The invention discloses a traditional Chinese medicine composition for treating perimenopausal dry eyes and a preparation method and application thereof, and relates to the technical field of traditional Chinese medicine formulas. The traditional Chinese medicine composition for treating the perimenopausal dry eye comprises herba epimedii, prepared rehmannia root, rhizoma anemarrhenae, cortex phellodendri, radix paeoniae alba, angelica sinensis, radix bupleuri, poria cocos and honey-fried licorice root. The traditional Chinese medicine composition for treating perimenopausal dry eye, namely the kidney-warming dry eye formula, has the functions of warming kidney, nourishing yin, soothing liver and strengthening spleen, can effectively improve perimenopausal symptoms such as dry eye, photophobia, asthenopia, foreign body sensation, burning sensation, soreness and weakness of waist and knees, dysphoria, irritability, hot sweating, insomnia, amnesia and the like of patients with perimenopausal dry eye, improves the estrogen level, and has the efficacy of treating perimenopausal dry eye. The ocular surface inflammatory response is inhibited, and the tear film stability is improved.

An aqueous micro shunt for treating dry eye syndrome comprises an axially oriented shaft, for insertion through a scleral wall portion of an eye and into an anterior chamber of the eye, and having an open distal end adapted to be fluidically connected to aqueous humor contained within the anterior chamber of the eye. First and second axially oriented lumens are defined within the axially oriented shaft, and a plate is fixedly mounted at a predetermined angle upon a proximal end of the axially oriented shaft. A slot is defined within the plate so as to be fluidically connected to the second axially oriented lumen defined within said axially oriented shaft such that aqueous fluid can flow from the anterior chamber of the eye, through the first and second lumens defined within the axially elongated shaft, and outwardly through the slot defined within the plate so as to flow over an ocular surface portion of the eye and thereby treat dry eye syndrome.

The invention relates to a traditional Chinese medicine composition for preventing and treating ocular surface injury caused by xerophthalmia and application thereof. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 20-40 parts of spica prunellae, 20-40 parts of radix astragali, 5-25 parts of rhizoma polygonati, 5-25 parts of folium mori and 5-25 parts of fructus crataegi. Compared with the prior art, the traditional Chinese medicine composition disclosed by the invention consists of five medicinal and edible Chinese herbal medicines, is simple and convenient to take, safe and free from side effects, and can be popularized and used as a medicine for preventing and treating xerophthalmia. The traditional Chinese medicine composition disclosed by the invention can be used for remarkably inhibiting the corneal injury related to the xerophthalmia, maintaining the number of conjunctival goblet cells and providing new treatment for relieving the ocular surface injury of the xerophthalmia.

The application discloses a kind of drug composition of synergistic targeting MMP-9 path and STING path and application thereof, belong to the technical field of ophthalmic drugs.The drug composition includes the final concentration 5~90 μM of Marimastat, the final concentration 2.5~10 μM of SN-011, the final concentration 0.1 vol % of DMSO and sterile PBS buffer solution.The drug composition of the application can efficiently, safely treat moderate to severe dry eye, effectively improve tear film stability, repair corneal epithelial barrier, inhibit ocular surface chronic inflammation, while reducing the risk of disease recurrence.

The invention discloses dexamethasone eye emulsion supramolecular hydrogel and a preparation method thereof, and belongs to the technical field of medicines. The dexamethasone eye emulsion supramolecular hydrogel is prepared from the following components in percentage by mass volume: 0.02 to 0.06 percent of dexamethasone, 0.5 to 5 percent of liquid oil, 1 to 6 percent of emulsifier and 1 to 5 percent of polyphenol. According to the dexamethasone ophthalmic emulsion supramolecular hydrogel provided by the invention, dexamethasone is used as a main drug, and a nanoemulsion is used as an insoluble drug carrier to improve the solubility of the dexamethasone ophthalmic emulsion supramolecular hydrogel; the emulsifier on the surface of the nanoemulsion can be self-assembled with polyphenol through hydrogen-bond interaction to form a supramolecular hydrogel network. After the preparation is dropped into the conjunctival sac, the drug-loaded nano-emulsion is gradually released and the free drug is further released under the shear thinning action caused by tear dilution and blinking, so that the long-acting treatment concentration is maintained on the ocular surface, and the defects that the drug is easily lost due to nasolacrimal duct drainage, the retention time of the ocular surface is short and the like in the traditional eye drops are effectively overcome.

This invention belongs to the field of pharmaceutical formulations and relates to a compound ophthalmic in-situ gel composition for treating ocular Demodex mite infection, its preparation method, and its application. By weight percentage, the compound ophthalmic in-situ gel composition for treating ocular Demodex mite infection comprises 0.1-2.0% of a nitroimidazole compound, 0.05-3.0% of an isoxazoline compound, 0.1-1.5% of a gelling polymer, 1.0-8.0% of a complex solubilizing system, 0.1-3.0% of pharmaceutically acceptable excipients, and the balance being water. The complex solubilizing system includes polyvinylpyrrolidone and cyclodextrin derivatives. This invention effectively solves the problem of poor solubility of isoxazoline drugs through a complex solubilizing system, and the combination of the two drugs has a significant synergistic acaricidal effect. Combined with a gelling polymer, it can achieve in-situ gelation on the ocular surface, prolong retention, and sustained drug release, with low ocular irritation, providing a highly effective, long-lasting, and safe new local treatment option for Demodex mite-related eye diseases.

A pharmaceutical composition to be applied to an ocular surface is disclosed that includes a quaternized chitosan derivative to provide antimicrobial activity against gram-negative bacteria, gram-positive bacteria, fungi, and viruses as an active ingredient. This is combined with a cellulose compound acting as a viscosity agent and demulcent to protect and lubricate mucous membrane surfaces. This is further combined with a humectant and tonicity agent to retain moisture on the ocular surface and maintain a comfortable osmolarity for the eye. This is further combined with a buffer / pH adjuster system configured to support a physiologically tolerable pH of about 6.0 to 8.0. Finally, this is combined with purified water as a diluent.

The invention provides an anterior segment transmission interference microscopic imaging device, method and system, and relates to the technical field of medical optical imaging and ophthalmic diagnosis. The single-frame imaging field of view is not less than 2mm * 1mm and is larger than that of a common clinical confocal microscope and a corneal endothelial mirror, so that the statistical reliability and the lesion detection rate can be improved; through a transmission interference mechanism, corneal nerves, epithelial cells and crystalline lens fine structures can be displayed in a high contrast manner, and the method is particularly suitable for low-scattering transparent tissues; a common-path optical structure is adopted, a reference arm or a high-speed scanning unit is not needed, and the system is small in size, low in cost and good in stability; in the examination process, contact with the ocular surface or introduction of a contrast agent is not needed, and discomfort and risks possibly caused by traditional contact type or intrusive type examination are avoided; the method can be used for corneal nerve evaluation, endothelial disease screening, crystalline lens microstructure observation and preoperative / postoperative follow-up visit.